Skip to main content
. 2021 May 28;205(2):142–149. doi: 10.1111/cei.13609

FIGURE 2.

FIGURE 2

Interleukin (IL)‐6 and IL‐10 in B cells. (a,b) Percentages of IL‐6+ B cells increased after CD40L/phorbol myristate acetate (PMA)/ionomycin stimulation in rheumatoid arthritis (RA) and in healthy subjects (HC), but not after collagen epitope stimulation. In RA, tofacitinib treatment increased IL‐6+ B cells. (c,d) Percentages of IL‐10+ B cells in RA were significantly reduced after collagen epitope stimulation (**P = 0.003 versus unstimulated B cells), but not in HC. IL10+ B cells significantly increased in tofacitinib‐treated RA B cell stimulated with collagen epitopes (***P = 0.01 versus RA B cells stimulated with collagen epitopes not treated with tofacitinib), while significantly decreased in the CD40L/PMA/ionomycin setting (*P = 0.005 RA B cells stimulated with CD40L/PMA/ionomycin not treated with tofacitinib versus RA B cells stimulated with CD40L/PMA/ionomycin + tofacitinib)